While proteogenomic technology is still in its early stages, it will likely make its way into the clinic over the next five to 10 years, said an FDA official.
The test, which measures the kinetics of amyloid beta isoforms in blood, could enable more efficient screening of patients for Alzheimer's drug trials.
The agencies said they're aiming to "accelerate the development of proteogenomic technologies and biomarkers, as it relates to precision medicine in cancer."
While actual clinical implementation remains distant, MALDI imaging technology has advanced to the point where it might feasibly be applied to pathology.
The company expects the deal will help it launch an immunostaining technology, expand into US pharma services, and establish itself as a genetic testing leader in Japan.
Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.
Based on a 537-patient validation study, the markers appear capable of detecting early-stage disease and could be useful for monitoring high-risk populations.
The company said it plans to use the funds to extend its commercial operations and develop new products broadly aimed at the life sciences research market.
Though still on the fringes of life science research, these instruments could be attractive for targeted applications due to their portability and simplicity.
The device allows more efficient delivery to mass specs of the charged droplets containing analytes of interest that are generated via electrospray ionization.
The study details the validation of the mass spec-based preterm birth test, which the company launched nationwide last month through its agreement with LabCorp.
The Triple Quad 4500MD LC-MS/MS system, which consists of the LC-MS/MS platform along with Sciex's Analyst MD, Cliquid MD, and MultiQuant MD software, can be used for in vitro diagnostics.
The approach uses the recombinase Cre along with next-generation sequencing to detect and identify protein-protein interactions in yeast two-hybrid experiments.
The organization named the institutions that will be performing the proteomic and proteogenomic analyses planned to for the five-year, $65 million effort.
The method will allow DIA-based studies of protein PTMs similar to what has been possible using conventional data-dependent acquisition mass spec approaches.
As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The researchers used a quantitative proteomics technology to determine whether ribosome heterogeneity exists as was previously theorized.
Positive Bioscience will offer Biodesix's liquid biopsy tests for non-small cell lung cancer in India.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
Researchers from the Netherlands Cancer Institute plan to spin out a company to use sequencing-based cellular network mapping to aid in drug development.
NPR reports that Turkish high school students will no longer study evolution.
Researchers report they sequenced and identified plant species in an "al fresco" laboratory.
An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.
In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.